News
Cytospire Therapeutics announces oversubscribed £61 million ($83m) Series A financing to advance pipeline of first-in-class pan-gamma delta T cell engagers into clinical trials for the treatment of cancer
Series A financing led by 4BIO Capital, with major new investors Servier Ventures, Sound Bioventures, British Business Bank and Criteria Bio Ventures, supported by existing investors Abingworth and LifeArc Ventures
Cytospire Therapeutics CEO, Natalie Mount, recognised as Woman Entrepreneur of the Year at 2025 Cancer Research Horizons Innovation and Entrepreneurship Awards
Cytospire Therapeutics CEO, Natalie Mount, recognised as Woman Entrepreneur of the Year at 2025 Cancer Research Horizons Innovation and Entrepreneurship Awards
Cytospire Therapeutics is a shortlisted nominee at the 2025 Cancer Research Horizons Innovation and Entrepreneurship Awards
Cytospire Therapeutics is delighted to have been shortlisted
UPCOMING EVENTS
Hanson Wade Bispecific Summit, London
7-9 July, 2026
Jefferies Healthcare Conference, London
16-19 November, 2026
PAST EVENTS
AACR Annual Meeting, San Diego
16-22 April, 2026
Cytospire Therapeutics will be attending PEGS Europe 2025, Lisbon
11-13 November, 2025
Cytospire Therapeutics will be attending BIO-Europe 2025, Vienna
3-5 November, 2025
